Current Report Filing (8-k)
July 08 2019 - 05:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): July 8, 2019
Kiwa
Bio-Tech Products Group Corporation
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-33167
|
|
77-0632186
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
3200
Guasti Road, Suite 100
Ontario,
CA
|
|
91761
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (626) 715-5855
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Item
5.02. Departure of Directors; Appointment of Directors.
On
July 8, 2019, the Board of Directors removed Yongling Song as as a member of the Board of Directors of Kiwa Bio-Tech Products
Group Corp.
On
July 8, 2019, the Board of Directors appointed Xiaoqiang Yu as as a member of the Board of Directors of Kiwa Bio-Tech Products
Group Corp.
Xiaoqiang
Yu (41)
Mr.
Yu has been involved in the Chinese fertilizer market since 1999, both in terms of market operation and corporate management.
Mr. Yu became Kiwa’s Sales and Marketing Director in June 2016. His responsibilities have focused on managing the overall
marketing strategy of Kiwa, market research, establishing and expanding sales channels, and accomplishing the company’s
sales goals.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
None
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
July 8, 2019
|
Kiwa
Bio-Tech Products Group Corporation
|
|
|
|
|
/s/
Yvonne Wang
|
|
By:
|
Yvonne
Wang
|
|
Title:
|
Chief
Executive Officer
|
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Mar 2023 to Mar 2024